NasdaqGS:PGENBiotechs
FDA Approval of First RRP Therapy Could Be a Game Changer for Precigen (PGEN)
Precigen recently held a special call to discuss the FDA approval of the first and only approved therapy for adults with recurrent respiratory papillomatosis (RRP).
This regulatory milestone not only introduces a new treatment option for a previously underserved condition but also signals a significant advance for the company in addressing rare diseases.
We'll explore how launching the first FDA-approved RRP therapy may reshape Precigen's investment narrative by expanding its clinical...